



























altera/ons	 were	 expected,	 as	 neuroinﬂamma/on	 may	 occur	 as	 a	 consequence	 of	
neuronal	loss	(FawceZ	and	Ashe,	1999).		
No	 other	 reports	 exist	 in	 veterinary	 literature	 about	 AQP4	 in	 epilep/c	 dog.	 The	
overexpression	of	AQP4	observed	in	epilep/c	dogs	 is	similar	to	the	one	described	in	
human	revised	bibliography	(Coulter	and	Steinhäuser,	2015)	
Immunohistochemical techniques used in the study. 









Citrate buffer 0.01M pH 6, 
20’ 96-98ºC water bath + 
30’ room temperature 
GFAP 
Rabbit polyclonal Anti-
Cow Glial Fibrillary 
Acidic Protein 
Dako Z0334 1:5000 
Citrate buffer 0.01M pH 6, 
20’ 96-98ºC water bath + 
30’ room temperature 
AQP4 Polyclonal Rabbit Anti-Aquaporin 4 Antibody, CT 
Millipore 
ab3594 1:800 Without pre-treatment 
Iba-1 Goat Polyclonal to Iba-1 Abcam ab5076 1:300 
Citrate buffer 0.01M pH 6, 
20’ 96-98ºC water bath + 
30’ room temperature 	

















































•  None	 of	 the	 studied	 epilep/c	 dogs	 showed	 histopathological	 and	
immunohistochemical	changes	corresponding	with	Hippocampal	Sclerosis.	
•  Only	the	epilep/c	cat	showed	a	remarkable	neuronal	 loss	and	neuroinﬂammatory	
changes	 similar	 to	 those	 described	 for	 human	 Hippocampal	 Sclerosis.	 These	
ﬁndings	conﬁrm	the	cat	as	a	useful	animal	model	for	epilepsy.		
•  AQP4	is	a	useful	biomarker	for	studying	epilepsy	in	both	dogs	and	cats.	
•  A	 further	 inves/ga/on	 in	 canine	 epilepsy	 histopathogeny	 is	 needed	 in	 order	 to	
state	whether	dogs	suﬀer	from	hippocampal	sclerosis.		




All	 these	 results	 conﬁrm	HS	 ﬁndings	 (histological	 and	 immunohistochemical)	 in	 one	





































dog	 and	 a	 control	 one	 showed	 no	 important	 differences	 except	 for	 the	 AQP4	
expression,	that	appeared		overexpressed	in	the	epilep/c	dog	court.	(2,5x)	
		





and	 granular	 cell	 dispersion,	 astroglial	 prolifera/on	 and	 ac/va/on	 and	 microglial	
prolifera/on.	(20x)	
